Recruiting
- Dec 6, 2019

NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM

Updated: Sep 21, 2022

Dara-KRd

NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

This study is being done because, despite major advances in therapy, MM is still considered an incurable disease. The purpose of this study is to determine the efficacy (how well it works) of the study treatment that combines the following drugs: daratumumab, carfilzomib, lenalidomide, dexamethasone in subjects who have a recent diagnosis of multiple myeloma (MM).

Sponsor

Wake Forest University Health Sciences

Collaborators

Amgen

Celgene

Janssen, LP

ClinicalTrials.gov Identifier: NCT04113018

Official Title: LCI-HEM-MYE-KRdD-001: Phase II Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

First Posted : October 2, 2019

Click here for details on ClinicalTrials.gov

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

* Carfilzomib (Kyprolis)

* Lenalidomide (Revlimid)